As shown in Figure 8B, the high-risk group was characterized by high expression of most immune checkpoint-related genes, including PDCD1, LAG3, CTLA-4, TIGIT, etc. Taken together, HCC patients with a high-risk score of IRGs may be more responsive to immunotherapies targeting the checkpoint molecules. This evidence concerns the gene CTLA4 and hepatocellular carcinoma.